<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049837</url>
  </required_header>
  <id_info>
    <org_study_id>LAB07-0233</org_study_id>
    <secondary_id>5R01CA157450-05</secondary_id>
    <secondary_id>5R01CA183793</secondary_id>
    <secondary_id>1R01CA205150-01</secondary_id>
    <nct_id>NCT05049837</nct_id>
  </id_info>
  <brief_title>PROSPECT - Profiling of Resistance Patterns &amp; Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification</brief_title>
  <official_title>PROSPECT - Profiling of Resistance Patterns &amp; Oncogenic Signaling Pathways in Evaluation of Cancers of the Thorax and Therapeutic Target Identification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this Project, we will use therapeutic target -focused (TTF) profiling, genome-wide mRNA&#xD;
      profiling and assessments of tumor phosphopeptides and DNA that are shed into the blood&#xD;
      stream to define how various molecular factors alone and in combination relate to resistance&#xD;
      to therapy, to prognosis, and to metastatic patterns at relapse. We will examine how the&#xD;
      presence of factors that drive cell growth, antagonize apoptosis, or confer resistance in&#xD;
      other ways may counter the effect of systemic therapies and/or promote rapid tumor&#xD;
      recurrence. In this way, we will identify new, previously unappreciated potential therapeutic&#xD;
      targets while also identifying which targets are most likely to increase resistance to&#xD;
      therapy and worsen prognosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
        1. To develop a therapeutic target -focused (TTF) profiling platform and to use it in vitro&#xD;
           to identify potential therapeutic targets associated with therapeutic resistance and to&#xD;
           develop novel approaches against these potential targets.&#xD;
&#xD;
        2. To use tumor tissue TTF profiling along with genome wide mRNA profiling, serum&#xD;
           phosphopeptide profiling and plasma DNA profiling to identify and evaluate molecular&#xD;
           targets and pathways that contribute to therapeutic sensitivity or resistance,&#xD;
           prognosis, and recurrence patterns in patients with operable non-small cell lung&#xD;
           carcinoma (NSCLC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2007</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To develop a therapeutic target -focused (TTF) profiling platform and to use it in vitro to identify potential therapeutic targets associated with therapeutic resistance and to develop novel approaches against these potential targets.</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">7200</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Cancer of Thorax</condition>
  <arm_group>
    <arm_group_label>Specific Aim 1</arm_group_label>
    <description>600 cases: two normal and two tumor formalin-fixed tissue samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Specific Aim 2</arm_group_label>
    <description>600 cases: two normal and two tumor formalin-fixed tissue samples.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Specific Aim 3</arm_group_label>
    <description>600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Specific Aim 4</arm_group_label>
    <description>600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Specific Aim 5</arm_group_label>
    <description>600 cases; two normal and two tumor formalin-fixed tissue samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Specific Aim 6</arm_group_label>
    <description>210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group Specific Aim 1</intervention_name>
    <description>600 cases: two normal and two tumor formalin-fixed tissue samples</description>
    <arm_group_label>Specific Aim 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group Specific Aim 2</intervention_name>
    <description>600 cases: two normal and two tumor formalin-fixed tissue samples.</description>
    <arm_group_label>Specific Aim 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group Specific Aim 3</intervention_name>
    <description>600 cases, including 150 patients who had received neoadjuvant therapy and 450 patients who had not. Two normal and two tumor formalin-fixed tissue samples</description>
    <arm_group_label>Specific Aim 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group Specific Aim 4</intervention_name>
    <description>600 cases; including 150 patients who will receive neoadjuvant chemotherapy, 150 patients who received or will receive postoperative adjuvant chemotherapy, and 300 patients who did not receive or will not receive neoadjuvant or adjuvant chemotherapy. Two normal and two tumor formalin-fixed tissue samples</description>
    <arm_group_label>Specific Aim 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group Specific Aim 5</intervention_name>
    <description>600 cases; two normal and two tumor formalin-fixed tissue samples</description>
    <arm_group_label>Specific Aim 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group Specific Aim 6</intervention_name>
    <description>210 cases (of the 600 above), one normal and one tumor formalin-fixed histology sections obtained from formalin-fixed and paraffin- embedded tissue samples.</description>
    <arm_group_label>Specific Aim 6</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        M D Anderson Cancer Center (Lung Cancer Patients)&#xD;
&#xD;
        Patients should be ones who have stage I-IIIA non-small cell lung cancer (NSCLC)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Eligible patients should be ones who have stage I-IIIA non-small cell lung cancer (NSCLC)&#xD;
        and undergo surgical resection with or without neoadjuvant chemotherapy as part of standard&#xD;
        treatment, and have a information of demographics, smoking history, preoperative clinical&#xD;
        data, and follow -up data including adjuvant therapy, relapse, and treatment at relapse.&#xD;
&#xD;
        We will include the three major NSCLC histologic subtypes, adenocarcinoma, squamous cell&#xD;
        carcinoma, and large cell carcinoma -&#xD;
&#xD;
        Exclusion Criteria: None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignacia Wistuba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignacio Wistuba, MD</last_name>
    <phone>713-563-9184</phone>
    <email>iiwistuba@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Caner Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Wistuba, MD</last_name>
      <phone>713-563-9184</phone>
      <email>iiwistuba@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

